Shunho Terminates HNB Plans Due to Policy Changes

Feb.08.2025
Shunho Terminates HNB Plans Due to Policy Changes
Investors question Shunho's progress on HNB manufacturing project; company terminates plans due to policy changes.

Recently, investors inquired on the investor interaction platform about Shunho Corporation (002565.SZ) and whether the company's previously planned "project to manufacture 200 million HNB wake-up sticks per year" is still progressing. If it has been terminated, they also asked if there are any similar new tobacco expansion plans.


In response, Shunho Corporation stated that due to adjustments in national policies, the construction of the project was difficult to proceed with. After the expiration of the project agreement, the company has reached a consensus with the relevant parties and signed the "Cancellation Agreement for the construction of the Green Electronic HNB Stick Manufacturing Project with an annual capacity of 200 million units". For further details, please refer to the announcement released by the company on August 17, 2024 (announcement number: 2024-050). Regarding the company's strategic planning in the new tobacco field, investors are advised to refer to the periodic reports that have been published.


We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

BAT plans to sell its stake in ITC Hotels, using proceeds to reduce debt
BAT plans to sell its stake in ITC Hotels, using proceeds to reduce debt
British American Tobacco (BAT) plans to sell all or part of its stake in ITC Hotels via an accelerated bookbuild, with the sale size expected to be up to 15.3% of the company’s shares. The company says the proceeds will be used to reduce debt and bring its leverage back within the target range.
Dec.05 by 2FIRSTS.ai
U.S. FDA Unveils Next-Generation Agentic AI Tool to Boost Review and Regulatory Efficiency
U.S. FDA Unveils Next-Generation Agentic AI Tool to Boost Review and Regulatory Efficiency
The U.S. FDA has announced the agency-wide deployment of new agentic AI capabilities, providing all employees with an optional multi-step task automation tool. Building on the broad adoption of its earlier large-language-model system, Elsa, the FDA aims to use this next-generation AI workflow to accelerate product review, regulatory oversight, and internal operations, while maintaining strict human supervision and data security.
Dec.02 by 2FIRSTS.ai
Belgian Drug Commissioner Warns of Hidden Opioids in Illegal Vapes
Belgian Drug Commissioner Warns of Hidden Opioids in Illegal Vapes
Belgium’s drug commissioner Ine Van Wymersch has warned that more than 80% of illegal refillable vape capsules seized in Belgium contain synthetic opioids, posing serious risks of early addiction among children. She told Euronews that these substances, which have no distinctive smell or color, could lead to opioid dependence from a young age.
Dec.08 by 2FIRSTS.ai
Harm Reduction Experts Warn: FCTC COP11 Policies Risk Marginalizing the Global South
Harm Reduction Experts Warn: FCTC COP11 Policies Risk Marginalizing the Global South
Two global tobacco harm reduction experts, in their submission to 2Firsts, argue that several COP11 policy proposals driven by high-income countries do not align with the capacities and conditions of low- and middle-income countries. They highlight research and funding gaps and call for a more equitable global support mechanism.
Nov.19
Kazakhstan’s Astana Baikonur District Fines Illegal Smokeless Tobacco Sales Over USD 5,800
Kazakhstan’s Astana Baikonur District Fines Illegal Smokeless Tobacco Sales Over USD 5,800
Authorities in Astana’s Baikonur District have intensified enforcement against illegal smokeless tobacco and related products in 2025. Police conducted 59 inspection raids, identifying 63 cases of illegal sales of smokeless tobacco (nasvay). Total fines imposed reached KZT 3,096,450(approximately USD 5,880). Officials said inspections and preventive outreach will continue.
Dec.29 by 2FIRSTS.ai
Juul, NJOY and Altria Clash Over Use of UCSF Public Documents in U.S. Patent Litigation
Juul, NJOY and Altria Clash Over Use of UCSF Public Documents in U.S. Patent Litigation
Juul Labs has asked a U.S. federal court to prevent NJOY and Altria from using documents stored in a public UCSF database in an ongoing patent lawsuit, arguing they are protected by attorney–client privilege. The defendants say the files have long been public and may contain evidence relevant to Juul’s patent conduct.
Dec.29 by 2FIRSTS.ai